Adverse events of pd-1 or pd-l1 inhibitors in triple-negative breast cancer: a systematic review and meta-analysis

HIGHLIGHTS

• who: Yixi Zhang et al. from the Department of Biostatistics, School of Public Health, Peking University, Beijing, China have published the Article: Adverse Events of PD-1 or PD-L1 Inhibitors in Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis, in the Journal: Life 2022, 12, x FOR PEER REVIEW of 30/06/2022
• what: The authors conducted a systematic review and meta-analysis to thoroughly evaluate the adverse events and the safety of PD-1 or PD-L1 inhibitors in TNBC patients based on extensive randomized clinical trials. Because the primary aims . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.